Search results
Results From The WOW.Com Content Network
Novartis is one of the largest pharmaceutical companies in the world, formed in 1996 by the merger of Ciba-Geigy and Sandoz. Ciba-Geigy was a result of the 1970 merger of two Swiss dye manufacturers, CIBA and Geigy, and had a history of producing drugs, agrochemicals and other products.
Find out the top 100 biotechnology and pharmaceutical companies ranked by their revenue in billion USD in 2023. See the change column to compare their performance over the years and the country and stock exchange they are traded on.
The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. [ 1 ] The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of APIs locally produced. [ 1 ]
Wednesday, Novartis AG (NYSE:NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient ...
A comprehensive list of independent companies and subsidiaries involved in human therapeutics, with their own Wikipedia articles. The list is alphabetical and includes both active and defunct firms, as well as their history, products and locations.
Sandoz is a public company that focuses on generic drugs and biosimilars. It was founded in 1886 in Basel, Switzerland, and became part of Novartis in 2003, before spinning off in 2023.
GSK plc is a British multinational company that produces drugs and vaccines. It was formed in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, and has a history of research and innovation in the industry.
Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [5] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [5] [6] It is taken ...